Mechanistically, miR-17-5p may also contribute to cardiac hypertrophy by inhibiting Mfn2 expression, activating the PI3K/AKT/mTOR pathway, and inhibiting autophagy (109). Here, MFN2 is linked to cardiac hypertrophy.